Axovant Sciences Ltd. appointed David Hung as its CEO and board director.
Hung replaces Axovant's founding CEO, Vivek Ramaswamy, who will remain on the company's board but focus largely on leading its parent Roivant Sciences.
Hung was the founder, president and CEO of Medivation Inc. until its acquisition by Pfizer Inc. in September 2016 for approximately $14 billion.
The company also appointed Marion McCourt as president and COO, and Kathryn Falberg and William Vernon as independent directors of Axovant.
McCourt was COO, whereas Falberg and Vernon were board directors at Medivation through its acquisition by Pfizer.